ERAS
Erasca, Inc.
$17.90
-0.63 (-3.40%)
At close · Jul 13
Market Cap
$5.57B
Shares
310,984,542
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.90
Open$18.44
Day$17.63–18.50
52W$1.33–24.28
Avg vol 30d5.6M
Short int32.3M · 10.4% float · 4.5d
Short vol55%
Last earningsMay 8, 2024
DataJul 2021–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.2 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+84%
above
Price vs 50-day avg
+32%
above
RSI (14)
61
neutral
MACD trend
Positive
52-week position
72%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+28%
trailing
6-month return
+86%
trailing
YTD return
+381%
this year
Relative strength
+78%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
7 of 226 funds reported for Jun 30 · net +834.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.39% of float · ▲ +2.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
226 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
+36%
Y/Y
Free cash flow
$-95.6M
Balance sheet
$73.8M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
6.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+84%
Bullish
Price vs 50-day avg
+32%
Bullish
RSI (14)
61
Neutral
MACD trend
Positive
Bullish
52-week position
72%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
7 of 226 funds reported for Jun 30 · net +834.2K sh shares · +2 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.39% of float · ▲ +2.6% MoM · 4.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
226 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $18 · 72%
52-wk high $24
vs 200-day avg +84%
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERAS
this stock
Erasca, Inc.
|
$5.57B | +381.2% | — | — | 10.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.89B | +5.9% | +46.2% | 28.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.52B | -14.0% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.76B | +4.2% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERAS | -5.0% | +27.8% | +86.1% | -2.3% | +381.2% |
| SPY | -0.3% | +1.6% | +8.3% | +0.3% | +9.9% |
| vs SPY | -4.8% | +26.2% | +77.8% | -2.6% | +371.3% |